In The United States Will Begin To Treat COVID-19 With Blood Plasma Of People Who Have Been Ill

Table of contents:

In The United States Will Begin To Treat COVID-19 With Blood Plasma Of People Who Have Been Ill
In The United States Will Begin To Treat COVID-19 With Blood Plasma Of People Who Have Been Ill
Video: In The United States Will Begin To Treat COVID-19 With Blood Plasma Of People Who Have Been Ill
Video: Using blood to treat Coronavirus (COVID-19) 2023, February
Anonim

In the United States will begin to treat COVID-19 with blood plasma of people who have been ill

On Tuesday, March 24, the US Food and Drug Administration (FDA) authorized the use of plasma from COVID-19 patients for experimental treatment of the disease.

In the United States will begin to treat COVID-19 with blood plasma of people who have been ill
In the United States will begin to treat COVID-19 with blood plasma of people who have been ill

Photo: James Hodgman /

At New York's Mount Sinai Hospital, doctors will soon begin experimental treatment of COVID-19 with plasma from patients who have recovered from the disease. Reported by the New York Times.

On Tuesday, March 24, the US Food and Drug Administration (FDA) authorized the use of plasma from COVID-19 patients for experimental treatment of the disease.

Plasma is called the liquid part of blood (blood without corpuscles). The blood plasma of people who have undergone COVID-19 contains many antibodies against the new coronavirus. The use of plasma with antibodies in the treatment of various infections has a long history.

This therapy is planned to be used for people with a course of moderate illness who have begun to experience difficulty breathing. Experimental treatment will not be prescribed for patients with severe complications.

A message in which Mount Sinai Hospital asks people who have been ill to donate blood to make therapeutic plasma has gone viral. Doctors told the New York Times that they quickly recruited 2,000 volunteers.

Whether the use of plasma obtained from COVID-19 patients will be successful is now difficult to predict. Qualitative (randomized, controlled) studies have not been conducted not only during this pandemic, but also during outbreaks of other coronavirus diseases (SARS, MERS). The treatment data for COVID-19 patients in China is very limited (10 patients) and has been published in an unreferenced journal.

Popular by topic